At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 25 enrolled
Drug / intervention
Cabalettadrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Multi-Center, Dose-Escalation Study, to Assess Safety, Tolerability and Efficacy of Intravenous Cabaletta® in OPMD Patients
In Brief
A Phase 2 clinical trial evaluating Cabaletta for Oculopharyngeal Muscular Dystrophy. Completed, enrolled 25 participants across 4 sites in 3 countries.
Detailed Summary
The Purpose of this study is to assess the Safety, Tolerability and Efficacy of Intravenous Cabaletta® in Oculopharyngeal Muscular Dystrophy (OPMD) Patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOculopharyngeal Muscular Dystrophy
CountriesCanada, Israel, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedDec 2013
Enrollment StartFeb 2014
Primary CompletionApr 2016
TodayJul 2026
First PostedDec 19, 2013
Enrollment StartFeb 1, 2014
Primary CompletionApr 1, 2016
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 12.5 years ago
Interventions
Cabalettadrug